A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Bristol-Myers Squibb
Beijing Biotech
Genmab
Radiopharm Theranostics, Ltd
Eisai Inc.
PMV Pharmaceuticals, Inc
Mayo Clinic
NeoImmuneTech
National Cancer Institute (NCI)
Genmab
Exscientia AI Limited
Amgen
Ocellaris Pharma, Inc.
Apollo Therapeutics Ltd
Avenzo Therapeutics, Inc.
BicycleTx Limited
Pfizer
BicycleTx Limited
Volastra Therapeutics, Inc.
Maastricht University Medical Center
Hadassah Medical Organization
TCR2 Therapeutics
Incyte Corporation
Cancer Research UK
NuCana plc
Hutchmed
University of California, Irvine
Medicenna Therapeutics, Inc.
Numab Therapeutics AG
Esperas Pharma Inc.
Kymab Limited
Cyteir Therapeutics, Inc.
Sellas Life Sciences Group
Mundipharma Research Limited
Salubris Biotherapeutics Inc
Cancer Research UK
Innolake Biopharm
pharmaand GmbH
Genmab
Eisai Inc.
Corcept Therapeutics
Tesaro, Inc.
Incyte Corporation
Incyte Corporation
Immune System Key Ltd
Gilead Sciences
Novartis
Incyte Corporation
NKGen Biotech, Inc.